DTP3 TFA

Research use only, not for human use.

DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 (10 μM; 1-21 days) causes the potent and tumor-selective induction of JNK activation and apoptosis.

DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 (10 μM; 1-21 days) causes the potent and tumor-selective induction of JNK activation and apoptosis, as shown by the appearance of phosphorylated JNK, as early as 24 hours[2]. DTP3 TFA (s.c.; 14.5 mg/kg/day; 28 days) has shown a dramatic shrinkage of the tumors, and virtually eradicates established subcutaneous myeloma xenografts in mice. DTP3 TFA (intravenous injection; 10 mg/kg/day) has t1/2 of 1.26 hours, CL of 27.13 ML/min/kg, and Vd of 2.80 L/kg.

——

Cell Cycle/DNA Damage

DNA/RNA Synthesis

GADD45β/MKK7

——

——

--

639.62

C28H36F3N7O7

>98% (HPLC)

H2O:100 mg/mL (156.34 mM; Need ultrasonic);DMSO:50 mg/mL (78.17 mM; Need ultrasonic)

Oc2ccc(C[C@@H](NC(C)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc1ccccc1)C(N)=O)cc2.FC(F)(F)C(=O)O

——

(-20℃)

With Ice Pack

≥ 2 years